Literature DB >> 14517376

Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells.

M Aonuma1, M Iwahana, Y Nakayama, K Hirotani, C Hattori, K Murakami, M Shibuya, N G Tanaka.   

Abstract

The aim of this study was to determine the role of tumor-derived angiogenic factors in solid tumor formation. We compared the angiogenic potential of tumorigenic and non-tumorigenic human tumor cell lines. All tumorigenic cell lines induced angiogenesis in vivo and their angiogenesis-inducing abilities were higher than those of the other non-tumorigenic cell lines. This in vivo angiogenic potential was well correlated with the in vitro endothelial cell growth-stimulating activity contained in the cell extract or conditioned medium of each cell line. The endothelial cell growth-stimulating activities of these cell lines were completely inhibited by neutralizing antibodies to basic fibroblast growth factor (bFGF), acidic FGF (aFGF) or vascular endothelial growth factor (VEGF). Furthermore, the levels of tumor-derived endothelial cell growth-stimulating activities depended on the amounts of angiogenic factors such as VEGF and bFGF produced by tumor cells. Although VEGF transcripts were detected in all of the cell lines by RT-PCR assay, the non-tumorigenic cell lines showed poor productivity of VEGF as well as FGFs and had less or non-potency for endothelial cell growth stimulation. These findings suggest that the increase in production of angiogenic factors by tumor cells is necessary for their in vivo angiogenic and tumorigenic potentials, and that VEGF and FGFs are the major mediators of tumor-induced angiogenesis.

Entities:  

Year:  1998        PMID: 14517376     DOI: 10.1023/a:1009054410624

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  5 in total

1.  Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression.

Authors:  M Aonuma; Y Saeki; T Akimoto; Y Nakayama; C Hattori; Y Yoshitake; K Nishikawa; M Shibuya; N G Tanaka
Journal:  Int J Exp Pathol       Date:  1999-10       Impact factor: 1.925

2.  Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors.

Authors:  Robert A Stull; Roya Tavassoli; Scot Kennedy; Steve Osborn; Rachel Harte; Yan Lu; Cheryl Napier; Arie Abo; Daniel J Chin
Journal:  BMC Genomics       Date:  2005-04-18       Impact factor: 3.969

3.  Molecular profiling of cervical cancer progression.

Authors:  T Hagemann; T Bozanovic; S Hooper; A Ljubic; V I F Slettenaar; J L Wilson; N Singh; S A Gayther; J H Shepherd; P O A Van Trappen
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

4.  YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment.

Authors:  Shashi K Gopal; David W Greening; Rommel A Mathias; Hong Ji; Alin Rai; Maoshan Chen; Hong-Jian Zhu; Richard J Simpson
Journal:  Oncotarget       Date:  2015-05-30

5.  Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.

Authors:  Ewa Maj; Beata Filip-Psurska; Magdalena Milczarek; Mateusz Psurski; Andrzej Kutner; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2017-12-15       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.